Energenesis Biomedical

What Energenesis Biomedical does

Energenesis Biomedical Co., Ltd. (華安醫學股份有限公司) is a Taiwan-based, publicly listed (TWSE: 6657) clinical-stage biopharmaceutical company founded in August 2012 and headquartered in Neihu Technology Park, Taipei. The company is built around its proprietary ENERGI drug development platform, which uses purine-based compounds to activate AMP-activated protein kinase (AMPK) and raise intracellular ATP levels, with the goal of restoring cellular self-healing across multiple disease areas. Energenesis has assembled a pipeline of roughly ten drug candidates spanning topical wound care (ENERGI-F703 and its F703DFU/F703VLU/F703EB/F703BS variants for diabetic foot ulcers, venous leg ulcers, epidermolysis bullosa, and pressure sores), dermatology (F701 for androgenetic alopecia, F711 for burns), metabolic disease (F702 for Type 2 diabetes), inflammation (F704 for IBD, F708 for asthma), neurodegeneration (F705 for Parkinson's, F707 for mitochondrial disease), cachexia (F706), a vaccine adjuvant (F709), and CKD-related hyperphosphatemia (F710). The most advanced asset, ENERGI-F703DFU, is in an active multi-country Phase III trial (NCT05930210) following Phase II results showing a 36.7% complete closure rate versus 9.1% vehicle control (P<0.05) over 12 weeks, with Phase II data slated for presentation at EWMA 2026 in Bremen, Germany.

The company operates a dual business model. Its primary economic engine today is a research-reagent and contract-research-services division: proprietary reagent brands Visual Protein (Western blot substrates, protein assays, cell lysis and fractionation kits, stains and buffers) and Topcells (CCK-8, MTT, Trypan Blue), distributed alongside exclusive Taiwan distribution rights for Lumiprobe fluorescent dyes and Rigaku Reagents protein crystallization products, plus a multi-omics service platform offering proteomics, transcriptomics, metabolomics, TransOmics integrated analysis, microbiota profiling, and exosome miRNA/proteomics analysis. Revenue is currently generated from this reagent-and-services business; the drug pipeline is pre-revenue, with future economics expected to flow through licensing, co-development partnerships, and eventual product commercialization following regulatory approval.

Energenesis pursues a multi-jurisdiction regulatory strategy with active INDs and clinical programs across the U.S. FDA and Taiwan TFDA, and has begun extending IP internationally with a Canadian national-phase patent granted in February 2026 for methods of treating diabetic ulcers. The company has 11–50 employees, no parent or subsidiary structure, and lists publicly on TWSE with a 2023 IPO. Distribution is currently direct (research reagents and services via the corporate website, email, and phone), with no commercial product distribution yet given the pre-approval status of the drug pipeline. Customer concentration and revenue split between drug and non-drug streams are not publicly disclosed, and revenue has been roughly flat over 2021–2025 while net losses have widened materially as R&D spending ramps to support multiple Phase II/III programs.

Name

Energenesis Biomedical

Legal name

華安醫學股份有限公司

Website

https://energenesis-biomedical.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Energenesis Biomedical is a Taipei-based, TWSE-listed clinical-stage biopharmaceutical company developing a pipeline of AMPK-activating drugs across wound care, metabolic, inflammatory, and neurodegenerative diseases, while operating a parallel research-reagent and multi-omics services business under the Visual Protein and Topcells brands.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

Keywords

• Drug development platform
• Wound healing therapeutics
• AMPK activation drugs
• Biotech research services
• Scientific reagent distribution

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. New Drug Development and Licensing: Pre-revenue clinical-stage biopharmaceutical company developing novel drugs through the ENERGI platform. Revenue expected from drug licensing, co-development partnerships, and eventual product commercialization upon regulatory approval.
2. Biotechnology Research Services: Contract research services providing proteomics, transcriptomics, metabolomics, TransOmics, microbiota analysis, and exosome miRNA/proteomics services to academic and pharmaceutical clients.
3. Scientific Reagent Sales: Sale of research reagents including Western blot reagents, cell culture supplements, protein separation/purification kits, protein quantification assays, stains and buffers, and cell application reagents under the Topcells and Visual Protein brands.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Energenesis Biomedical operates a proprietary ENERGI drug development platform that uses purine compounds to activate AMP-activated protein kinase (AMPK), increasing intracellular ATP levels to promote cellular self-healing across multiple therapeutic areas. The company develops a pipeline of topical and oral drug candidates targeting wound care, alopecia, Parkinson's disease, type 2 diabetes, inflammatory bowel disease, asthma, cachexia, and rare skin diseases, complemented by a research reagent business (Visual Protein and Topcells brands) and fee-for-service biotech laboratory platforms (proteomics, transcriptomics, metabolomics, microbiota, exosome analysis).

Product overview

Energenesis Biomedical (華安醫學股份有限公司) operates as a dual-focus biopharmaceutical and biotech services company. Its core innovation is the proprietary ENERGI drug development platform, which uses purine-based compounds to activate AMPK and increase cellular ATP levels, enabling self-healing across multiple therapeutic areas. The drug pipeline spans 10 candidates: ENERGI-F703 (diabetic foot ulcers, Phase III) and its variants F703DFU, F703VLU, F703EB, and F703BS for different chronic wound types; ENERGI-F701 (alopecia, Phase II completed, Phase III planned); ENERGI-F711 (burns); ENERGI-F702 (Type 2 diabetes); ENERGI-F704 (inflammatory bowel disease); ENERGI-F708 (asthma); ENERGI-F705 and F707 (Parkinson's disease and mitochondrial diseases); ENERGI-F706 (cachexia); ENERGI-F709 (vaccine adjuvant); and ENERGI-F710 (blood phosphate control). In parallel, the company operates a research reagent and services division, distributing Visual Protein branded products (Western blot reagents, protein assays, cell culture additives) and offering fee-for-service biotech laboratory platforms covering proteomics, transcriptomics, metabolomics, TransOmics, microbiota analysis, and exosome analysis.

Differentiator

Problem solved

Functional benefit

Brands

• Topcells: Cell application reagents brand including CCK-8 cell viability assay kit, MTT cell counting assay kit, and Trypan Blue solution for cell counting.
• ENERGI Platform

Products and services

• ENERGI-F703 (Diabetic Foot Ulcer Topical Gel) Topical gel for treating diabetic foot ulcers that enhances chronic wound healing by modulating cellular energy pathways and increasing intracellular ATP to promote cell regeneration. Currently in Phase III clinical trial (NCT05930210).
• ENERGI-F703VLU (Venous Leg Ulcer Topical Gel) Topical gel for treating lower limb venous leg ulcers; Phase II trial ongoing in Taiwan.
• ENERGI-F703EB (Epidermolysis Bullosa Topical Cream) Topical cream for treating wounds in hereditary epidermolysis bullosa (EB); Phase II clinical trials approved by both US FDA and Taiwan FDA.
• ENERGI-F701 (Alopecia Topical Tonic) Topical tonic for treating androgenetic alopecia that delays hair follicle aging and extends hair cycle by increasing ATP in dermal papilla cells through AMPK activation.
• ENERGI-F711 (Burn Wound Topical Cream) Topical burn cream for treating second-degree and above burn wounds; demonstrated to inhibit inflammation and accelerate wound healing in animal models.
• ENERGI-F702 (Type 2 Diabetes Oral Drug) Oral drug for blood sugar control and Type 2 diabetes treatment; shown to stimulate GLUT4 expression and increase cellular glucose uptake without causing weight gain in preclinical studies.
• ENERGI-F704 (Inflammatory Bowel Disease Oral Drug) Oral drug for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease; preclinical animal studies demonstrated reduction of intestinal inflammation.
• ENERGI-F705 (Parkinson's Disease Oral Drug) Oral drug for Parkinson's disease that increases ATP in neural cells and increases mitochondria in neural microglial cells via the AMPK/PGC-alpha pathway. Completed Phase I enrollment; planning Phase I IND submission.
• Proteomics Service Platform Contract research service providing protein identification, label-free quantification proteomics with systems biology analysis, post-translational modification analysis, and phosphoproteomics analysis using LC-MS/MS.
• Transcriptomics Service Platform Contract research service offering RNA-seq and systems biology analysis using next-generation sequencing to sequence and quantify mRNA, compare against databases, and analyze mRNA expression changes and metabolic pathways.
• Metabolomics Service Platform Contract research service offering targeted metabolomics using standard samples, tandem mass spectrometry (MS/MS), and online database comparison for metabolite structural analysis, including short/long-chain fatty acid, amino acid, organic acid, and environmental hormone detection.
• Microbiota Analysis Service Contract research service for analyzing human gastrointestinal and soil microbiota composition using 16S rRNA gene sequencing and bioinformatics comparison to understand microbial community structure and associations with disease or environmental changes.
• Visual Protein Research Reagents Branded line of scientific research reagents including Western blot chemiluminescent substrates, blocking buffers, protein extraction and fractionation kits, cell culture additives (HybriMore, CytoMore), and protein quantification assays (Bradford, BCA) sold to research laboratories.
• Topcells Cell Application Reagents Branded line of cell viability assay reagents including CCK-8 cell counting kit (single-reagent format), MTT cell counting assay kit, and 0.4% Trypan Blue solution for live/dead cell distinction.

Quantifiable outcome

• ENERGI-F703 Phase II: 36.7% complete closure rate vs 9.1% vehicle control (P<0.05) over 12 weeks for diabetic foot ulcers

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• Taiwan EB Association (台灣泡泡龍病友協會)minorOthers · 24 October 2025Charitable partnership supporting rare disease patients with epidermolysis bullosa (butterfly disease). Company sponsored the 'Beyond Pain, I Want to Say...' event organized with National Cheng Kung University USR program to support patients' voices and dignity.
• LumiprobeminorChannel Partner/ Reseller/ DistributorExclusive distribution partnership for Lumiprobe Corporation's molecular biology research reagents including fluorescent dyes (Fluorophore Dyes) and reactive dyes for microscopy, fluorescence polarization, PCR/qPCR, oligonucleotide synthesis, near-infrared imaging, and copper-free click chemistry applications in Taiwan market.
• Rigaku ReagentsminorChannel Partner/ Reseller/ DistributorExclusive distribution partnership for Rigaku Reagents protein crystallization research products including professional protein research reagents, consumables and equipment widely recognized internationally for protein crystallization studies.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• MediWound: Clinical-stage wound-care company developing enzymatic debridement and topical biologics for diabetic foot ulcers and burns. Directly comparable to Energenesis as a small-cap, single-platform wound-care biotech with a lead asset in DFU.
• Organogenesis Holdings: Commercial-stage regenerative medicine company selling skin substitutes and wound-care biologics (e.g., Apligraf, Dermagraft) for diabetic foot ulcers and chronic wounds. Comparable as a competing DFU therapy developer with US market presence.
• Vericel Corporation: Specialty regenerative medicine company developing cell-therapy products for severe burns and chronic wounds. Comparable as a late-clinical/commercial wound-care biologics specialist.
• MiMedx Group: Regenerative medicine company marketing placental-tissue allografts for chronic wounds including diabetic foot ulcers. Directly comparable as a US-focused wound-care biologics player competing for the same prescribing physicians.
• Anika Therapeutics: Specialty regenerative medicine company with hyaluronic-acid-based products for wound healing and osteoarthritis. Comparable as a mid-sized wound-care and tissue-repair biologics specialist.

Broad incumbents

• Smith+Nephew: Global medical device incumbent with a large Advanced Wound Management franchise including skin substitutes and DFU products. Comparable as a broad incumbent that Energenesis would partner with or compete against for US/EU wound-care distribution.
• Coloplast: Global leader in wound care and ostomy with a major DFU and chronic-wound portfolio. Comparable as a broad incumbent and potential strategic acquirer/partner for Energenesis's wound-care assets.
• ConvaTec Group: Global medical-products company with a substantial Advanced Wound Care business serving DFU patients. Comparable as a broad incumbent competing for the same wound-care prescribing channels.
• Integra LifeSciences: Medical-technology company with regenerative-tissue and wound-care products used in chronic wounds and burns. Comparable as a broad incumbent with overlapping wound-healing and tissue-regeneration capabilities.

Emerging players

• CytoTools AG: European clinical-stage biotech developing topical wound-healing agents for diabetic foot ulcers. Comparable as a smaller emerging peer in the same DFU topical-therapeutic niche with parallel clinical-stage positioning.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=NK96ke70QSo

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Energenesis Biomedical